Exercise Improves Lung Cancer Patients’ Quality of Life During Immunotherapy | 2026 ELCC Findings

The news coming out of the 2026 European Lung Cancer Congress in Copenhagen is offering a glimmer of hope for patients battling non-minor cell lung cancer, and it’s a conversation that’s particularly relevant right here in Chicago. While the initial findings focus on the benefits of supervised exercise for those undergoing immunotherapy, the broader implications touch on quality of life, treatment responsiveness, and the evolving landscape of cancer care – all factors deeply felt by individuals and families across the Midwest.

The Impact of Exercise on Lung Cancer Patients Undergoing Immunotherapy

Researchers from Greece presented compelling data demonstrating that supervised exercise significantly improves functional capacity and quality of life for patients with advanced lung cancer receiving immunotherapy, either alone or in combination with chemotherapy. This isn’t just about feeling better; it’s about maintaining independence and actively participating in life during a challenging time. The study, involving 42 participants, revealed that those in the exercise intervention group experienced a notable increase in their 6-minute walk test distance, a key indicator of functional capacity. Conversely, the control group showed no improvement and, in fact, experienced a worsening of symptom burden.

Understanding the Study Design and Key Findings

The study meticulously compared an intervention group – 18 patients engaged in an 8-week supervised outpatient exercise program – with a “usual care” group of 24 patients. Crucially, a reference group of 24 healthy individuals was included for comparison. The primary endpoint, change in functional capacity, was assessed using the 6-minute walk test. Secondary endpoints delved into physical function, inflammatory markers, oncologic outcomes, and, importantly, quality of life. The median follow-up period was 18.5 months, providing a reasonable timeframe for observing trends.

Beyond the improvement in walking distance, the exercise group also showed gains in muscle strength, physical performance, fine motor dexterity, and overall quality of life. Interestingly, researchers observed a significant reduction in the neutrophil-to-lymphocyte ratio in the exercise group, suggesting a positive impact on the immune system. While the study didn’t find a statistically significant difference in progression-free survival between the groups, exploratory analyses hinted that the effectiveness of exercise might vary depending on the specific treatment regimen. The overall response rate was comparable (22.2% vs 29.2%), and exercise wasn’t linked to changes in objective response rate, though a numerical difference in progression-free survival was noted.

The Broader Context: Immunotherapy Advances and Unmet Needs

These findings arrive at a pivotal moment in lung cancer treatment. Immunotherapy has revolutionized care for many, but it doesn’t work for everyone, and even when it does, patients can still experience disease progression. As Dr. Marina Garassino of the University of Chicago, IL, USA, pointed out, there’s a significant unmet need for effective treatments for patients whose disease progresses after immunotherapy, particularly those without actionable genetic alterations that would qualify them for targeted therapies. This is where the PRESERVE-003 trial, also presented at the European Lung Cancer Congress, offers another layer of optimism. Early results from stage 1 of that trial indicate that gotistobart, a novel anti-CTLA-4 antibody, improved overall survival in patients with metastatic squamous NSCLC who had progressed on anti-PD-(L)1 therapy.

The PRESERVE-003 trial, as reported by ESMO Daily Reporter, showed a hazard ratio of 0.46 (95% CI 0.25–0.84) favoring gotistobart over docetaxel, with a median OS not reached in the gotistobart group compared to 9.95 months in the docetaxel group. This suggests a potentially significant benefit for patients who have exhausted other treatment options. The 12-month progression-free survival rate was also markedly higher with gotistobart (25.2%) compared to docetaxel (0%). These advancements, coupled with the positive impact of exercise, paint a more hopeful picture for lung cancer patients in Chicago and beyond.

Navigating Lung Cancer Care in Chicago: A Local Resource Guide

Given my background in healthcare administration and a focus on patient advocacy, I understand that navigating a lung cancer diagnosis and treatment plan can be incredibly overwhelming, especially in a city as large and complex as Chicago. If these trends – the increasing importance of immunotherapy, the potential of fresh therapies like gotistobart, and the demonstrable benefits of exercise – are impacting you or a loved one in the Chicago area, here are three types of local professionals you should consider consulting:

Oncologic Rehabilitation Specialists

These professionals are specifically trained to design and implement exercise programs tailored to the needs of cancer patients. Look for someone with a certification in cancer rehabilitation and experience working with lung cancer patients undergoing immunotherapy. They can help you create a safe and effective exercise plan to improve your functional capacity and quality of life. Consider specialists affiliated with institutions like Northwestern Memorial Hospital or the University of Chicago Medical Center.

Lung Cancer Support Groups & Patient Navigators

Facing a cancer diagnosis is emotionally taxing. A skilled patient navigator can help you understand your treatment options, connect with resources, and manage the logistical challenges of care. Support groups provide a safe space to share experiences and connect with others facing similar challenges. The American Cancer Society has a strong presence in Illinois and can connect you with local resources.

Board-Certified Medical Oncologists Specializing in Thoracic Oncology

Finding an oncologist with deep expertise in lung cancer is paramount. Look for a physician board-certified in medical oncology with a subspecialty in thoracic oncology. They should be actively involved in clinical trials and have experience with the latest immunotherapy regimens and emerging therapies like gotistobart. Hospitals like Rush University Medical Center and Loyola University Medical Center have renowned thoracic oncology programs.

Ready to find trusted professionals? Browse our complete directory of top-rated healthcare experts in the Chicago area today.